M&As this week: Zimmer Biomet, Merz Pharma, StemCells

18 August 2016 (Last Updated August 18th, 2016 18:30)

Zimmer Biomet Holdings has announced the acquisition of CD Diagnostics in a move to foster its signature solutions.

Zimmer Biomet Holdings has announced the acquisition of CD Diagnostics in a move to foster its signature solutions.

The target company develops immunoassays and biomarker testing for improving patient outcomes.

The acquisition will also provide a boost to Zimmer Biomet’s mission to provide comprehensive musculoskeletal healthcare.

"The acquisition will also provide a boost to Zimmer Biomet’s mission to provide comprehensive musculoskeletal healthcare."

In a move to expand its aesthetic portfolio, specialty healthcare company Merz North America has acquired ON Light Sciences, a US-based medical device company that develops technologies to enhance laser-based dermatologic procedures.

The acquisition will add ON Light’s FDA-cleared and CE-marked laser tattoo removal patch, DeScribe Transparent PFD (perfluorodecalin), to Merz’s existing portfolio complementing its diversified portfolio of products, which includes the Ultherapy and Cellfina devices.

StemCells, along with its wholly-owned subsidiary C&RD Israel, (Merger Sub), has agreed to acquire Microbot Medical, in a move develop robotics-based medical devices to treat cerebrospinal fluid and gastrointestinal disorders.

The companies have entered a definitive merger agreement pursuant to which, Merger Sub will be merged with and into Microbot Medical, which will then become a wholly-owned subsidiary of StemCells.

Concurrently, StemCells has raised $2m through private placement of 5% secured notes to fund the acquisition.